Physician

Alexander Marshall Helfand

According to 2025 Medicare claims, Alexander Helfand (NPI: 1639525850) practices hematology/oncology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is ALLEGHENY CLINIC MEDICAL ONCOLOGY (NPI: 1831143403; TIN: 113683376) and primary practice location at 15212-4737.

Helfand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 107 traditional Medicare patients, billed 284 HCPCS/CPT codes, and received $22,273 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 456 prescription claims across 81 beneficiaries totaling $1,414,279 in drug costs, led by Inlyta (Axitinib). Open Payments data shows 36 records totaling $10,685. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $35,602 to $1,414,279. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$11K$22K2022 Medicare payment: $5,630 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $18,666 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $22,273 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
20222752$5,630
2023115187$18,666
2024107284$22,273

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$707K$1.4M2016 Drug cost: $35,602 (USD; Tot_Drug_Cst)2017 Drug cost: $130,349 (USD; Tot_Drug_Cst)2018 Drug cost: $78,287 (USD; Tot_Drug_Cst)2019 Drug cost: $55,931 (USD; Tot_Drug_Cst)2020 Drug cost: $8,319 (USD; Tot_Drug_Cst)2021 Drug cost: $5,387 (USD; Tot_Drug_Cst)2022 Drug cost: $20,318 (USD; Tot_Drug_Cst)2023 Drug cost: $415,903 (USD; Tot_Drug_Cst)2024 Drug cost: $1,414,279 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
201653328$35,602
20171241,420$130,349
2018941,068$78,287
201950683$55,931
202033155$8,319
202139152$5,387
20221974$20,318
202351234$415,903
202481456$1,414,279

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99223Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes3232$131
99215Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more2859$105
99233Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes2130$89
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more3051$71
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's2659$12

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
InlytaAxitinib17480$328,682
NubeqaDarolutamide19570$249,785
Abiraterone AcetateAbiraterone Acetate481,440$136,093
EliquisApixaban11330$6,433
Levothyroxine SodiumLevothyroxine Sodium351,350$385

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.36$10,685Bayer Healthcare Pharmaceuticals Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Alexander Marshall Helfand?

Tedicare shows public-source Medicare data for Alexander Marshall Helfand (NPI 1639525850), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander Marshall Helfand have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alexander Marshall Helfand?

Alexander Marshall Helfand is linked to ALLEGHENY CLINIC MEDICAL ONCOLOGY (billing NPI 1831143403) in the available physician profile data.

Does Alexander Marshall Helfand have Open Payments data?

Alexander Marshall Helfand has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.